QL1203

DRUG2 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Healthy MalesMetastatic Colorectal Cancer

Phase 1

Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.

Qilu Pharmaceutical Co., Ltd.Healthy Males

Start: 2019-10-28End: 2020-09-30Target: 94Updated: 2020-05-19

Phase 3

QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety

Qilu Pharmaceutical Co., Ltd.Metastatic Colorectal Cancer

Start: 2020-01-20End: 2025-07-30Target: 590Updated: 2023-05-26

Related Papers

QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial.

Journal of Clinical Oncology2025-01-27